• ENDRA regained Nasdaq compliance with the $2.5 million minimum stockholders’ equity rule, based on a July 8 notice.
• The deficiency was flagged April 20 following the 2025 Form 10-K; a Nasdaq hearing took place May 28.
• Nasdaq placed ENDRA under a one-year discretionary panel monitor starting July 1, 2026.
• Any new listing-rule breach during monitoring could trigger a delisting determination without a standard compliance plan period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ENDRA Life Sciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-076526), on July 09, 2026, and is solely responsible for the information contained therein.